GeneDx is trading at $66.43, up 5.88%, with no confirmed company-specific catalyst identified as of 9:45 a.m. on October 28, 2026.
- A finance update at 9:38 a.m. also reported no new company, sector, or macro catalyst.
- Biotech-sector strength may be contributing: XBI is up 2.18%, while major indexes are nearly flat.
- GeneDx’s long-read sequencing announcement predates this session and does not establish a direct cause.